Evidence map›Paper›PMID 42126794›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Oligopeptides/DNA Coacervate Droplets as Macromolecular Delivery Microcarriers.

Linyi Zhang, Chong Wang, Mengqi Han, Yi Yang, Teng Ma, Luoran Shang

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Linyi ZhangShanghai Key Laboratory of Medical Epigenetics, Shanghai Xuhui Central Hospital, Zhongshan-Xuhui Hospital, International Co-laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology, Institutes of Biomedical Sciences), Fudan University, Shanghai, China.
Chong WangDepartment of Rheumatology and Immunology, School of Biological Science and Medical Engineering, Nanjing Drum Tower Hospital, Southeast University, Nanjing, China.
Mengqi HanShanghai Key Laboratory of Medical Epigenetics, Shanghai Xuhui Central Hospital, Zhongshan-Xuhui Hospital, International Co-laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology, Institutes of Biomedical Sciences), Fudan University, Shanghai, China.
Yi YangDepartment of Cardiovascular Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Teng MaDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Luoran ShangShanghai Key Laboratory of Medical Epigenetics, Shanghai Xuhui Central Hospital, Zhongshan-Xuhui Hospital, International Co-laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology, Institutes of Biomedical Sciences), Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0001-7458-9100

Funding

Shenzhen Medical Research Fund B2401007
6 · The paper itself

Abstract

Macromolecular therapeutics demonstrate significant advantages and potential for treating diverse diseases. However, their intrinsic physicochemical properties often hinder the selection of suitable carriers for efficient intracellular delivery. Here, we develop coacervates formed via liquid-liquid phase separation of oligopeptides and DNA as macromolecular carriers for cellular membrane translocation. These materials enable the efficient recruitment and release of biomacromolecules, including proteins and enzymes. Notably, our experimental data suggest that their uptake may not be entirely identical to classical endocytic pathways and instead involves cholesterol-dependent lipid raft interactions, indicating a mechanism that may be distinct from canonical clathrin-mediated endocytosis. Upon reaching the cytoplasm, the DNA component of the coacervates is degraded by intracellular DNA-processing enzymes, leading to coacervate disassembly and subsequent release of the therapeutic macromolecules. Together, these coacervates establish a generalizable platform for intracellular delivery of macromolecular therapeutics, integrating membrane translocation with programmable cytosolic release.

Indexed as

DNADrug CarriersDrug Delivery SystemsMacromolecular SubstancesOligopeptidesAnimalsEndocytosisHumansPhase SeparationDNADrug CarriersMacromolecular SubstancesOligopeptideschemistrycoacervatedrug deliveryintracellular drug deliverymacromoleculephase separation process

Identifiers

PMID42126794
PMCPMC13335948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.